| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
December 21, 2010 |
|
|
| |
|
|
| |
|
|
|
The New York Academy of Sciences, New York City
2011-03-09
During the past decade there has been a marked decline in the number of novel drugs developed and approved for treatment of schizophrenia despite a significant investment in research and development by the pharmaceutical industry. The goal of this conference is to facilitate the translation of discoveries in basic neuroscience into the development of innovative pharmacological agents for the treatment of schizophrenia by convening and encouraging dialogue among clinical, translational and basic neuroscientists. Plenary sessions will include discussion of genetic and epigenetic approaches to studying schizophrenia; new molecular targets and approaches to small molecule therapeutics; and the relationship between genes, function, and clinical symptoms.
|
|
|
|
|
|
|
|
Organized by:
|
|
The New York Academy of Sciences |
|
|
Invited Speakers:
|
|
Keynote Speakers Eric J.Nestler, MD, PhD Mount Sinai Medical Center Edward Scolnick, MD The Broad Institute of Massachusetts Institute of Technology and Harvard University Patrick F.Sullivan, MD The University of North Carolina at Chapel Hill Speakers Marc Caron, PhD Duke University Medical Center P. Jeffrey Conn, PhD Vanderbilt University Medical Center Alessandro Guidotti, MD University of Illinois at Chicago Stephen Haggarty, PhD Harvard Medical School Jeffrey Lieberman, MD Columbia University Medical Center Bita Moghaddam, PhD University of Pittsburgh
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2011/01/14
|
|
|
|
|
|
|
|
Registration:
|
|
http://www.nyas.org/Events/Detail.aspx?cid=55938b51-f0d8-4d2b-aab7-de7436c96440
|
|
|
E-mail:
|
|
cau@nyas.org
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|